MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Firm” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage firm centered on stem cell-based therapies, in the present day introduced that Lance Alstodt, BioRestorative’s Chairman and CEO, together with Francisco Silva, Vice President of Analysis and Growth, have been invited to ring the closing bell at Nasdaq’s inventory market closing on Monday, February 7th at 4:00 PM ET in celebration of BioRestoriative’s uplisting to Nasdaq.
The ceremony will start at roughly 3:45PM ET and might be considered reside at https://livestream.com/accounts/27896496/events/9988418 .
“We’re honored to ring the closing bell in celebration of our latest uplisting. Our purpose is to validate our know-how by means of the regulatory course of positioning the Firm as a pacesetter within the world mobile remedy market,” commented Mr. Alstodt.
“Over the previous decade, we now have constructed a powerful basis of science, scientific translation and mental property and we sit up for increasing our pipeline into the clinic and growing therapeutics to assist these with unmet medical wants,” stated Mr.Silva.
Mr. Alstodt added, “We want to thank all of our workers for his or her laborious work and the unimaginable milestones we now have achieved to this point. We’re very excited to take the following step in our development story as we proceed to boost BioRestorative’s profile and execute on our strategic plan as a publicly-traded firm on Nasdaq.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. Our two core applications, as described beneath, relate to the therapy of disc/backbone illness and metabolic problems:
• Disc/Backbone Program (brtxDISC™): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product will likely be used for the non-surgical therapy of painful lumbosacral disc problems or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary know-how and includes amassing a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The therapy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who probably face the prospect of surgical procedure. We’ve obtained authorization from the Meals and Drug Administration to begin a Part 2 scientific trial utilizing BRTX-100 to deal with power decrease again ache arising from degenerative disc illness.
• Metabolic Program (ThermoStem®): We’re growing a cell-based remedy candidate to focus on weight problems and metabolic problems utilizing brown adipose (fats) derived stem cells to generate brown adipose tissue (“BAT”). BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be accountable for further caloric burning in addition to decreased glucose and lipid ranges. Researchers have discovered that individuals with greater ranges of brown fats might have a decreased threat for weight problems and diabetes.
Ahead-Wanting Statements
This press launch incorporates “forward-looking statements” throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended, and such forward-looking statements are made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. You might be cautioned that such statements are topic to a large number of dangers and uncertainties that might trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements on account of varied components and different dangers, together with, with out limitation, these set forth within the Firm’s newest Type 10-Ok filed with the Securities and Trade Fee. It is best to think about these components in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.
CONTACT:
E mail: ir@biorestorative.com
